4224 Campus Point Court
Suite 210
San Diego, CA 92121
United States
858 202 6300
https://www.regulusrx.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 30
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Joseph P. Hagan M.B.A. | CEO & Director | 898,38k | S.O. | 1969 |
Ms. Crispina Calsada CPA | Chief Financial Officer | 543,12k | S.O. | 1970 |
Mr. Christopher Ray Aker J.D. | Senior VP, General Counsel & Corporate Secretary | 539,97k | S.O. | 1961 |
Dr. Preston S. Klassen M.D., M.H.S. | President, Head of Research & Development and Director | S.O. | S.O. | 1969 |
Mr. Daniel J. Penksa | VP of Finance & Controller | S.O. | S.O. | 1986 |
Dr. Claire Susan Padgett M.S., M.T., Ph.D. | Senior Vice President of Clinical Operations | S.O. | S.O. | S.O. |
Dr. Rekha Garg M.D., M.S. | Senior Vice President of Clinical Development & Regulatory | S.O. | S.O. | S.O. |
Mr. Edmund Lee Ph.D. | Vice President of Translational Medicine | S.O. | S.O. | S.O. |
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
L’ISS Governance QualityScore de Regulus Therapeutics Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..